HB2380 directs the Secretary of Health and Human Resources, in consultation with the Attorney General, to convene a Pharmacy Benefits Manager and Third-Party Administrator Oversight Work Group. The work group is charged with studying the effects of the U.S. Supreme Court’s Rutledge decision on pharmacy benefit managers (PBMs), examining PBM and third-party administrator practices in Virginia, and developing legislative recommendations to lower prescription drug and health care costs, improve transparency, reduce administrative barriers, and support better health outcomes.
The bill also requires the work group to explore ways to promote generic drug manufacturing in the Commonwealth, including possible collaboration with research institutions such as the Medicines for All Institute at Virginia Commonwealth University. The work group must include representatives from state agencies, the pharmaceutical industry, consumer advocates, health care providers, and other stakeholders, and it must submit a report with findings and specific legislative proposals by November 1, 2026.
Impact
The bill does not itself change substantive Virginia law; instead, it creates an advisory and study process within state government to evaluate PBM and third-party administrator regulation and to recommend future legislation. Its practical impact would be to bring together regulators, industry, consumer groups, and health care stakeholders to identify potential statutory or regulatory reforms affecting prescription drug pricing, insurance administration, and transparency. It also signals legislative interest in expanding in-state generic drug manufacturing and related research partnerships.
Sentiment
The available voting history suggests the bill was not controversial at the committee stage, as it was tabled in Rules on a 14-0 vote. The bill’s stated goals—lowering drug costs, improving transparency, and reducing health care expenses—are framed in broadly bipartisan and consumer-friendly terms. No committee transcript is available, so there is no recorded debate reflecting opposition or support beyond the unanimous procedural vote.
Contention
The main potential points of contention are likely to involve the regulation of pharmacy benefits managers and third-party administrators, especially because PBM oversight often raises disputes over pricing practices, reimbursement rules, and administrative burdens on insurers and pharmacies. The inclusion of pharmaceutical industry representatives alongside consumer advocates and health care providers suggests the work group is intended to balance competing interests. Another possible area of debate is the bill’s reference to the Rutledge decision and whether Virginia should pursue stronger state-level intervention in prescription drug markets versus relying on existing insurance and market structures.